Analysts Set Qiagen N.V. (NYSE:QGEN) PT at $49.61

Shares of Qiagen N.V. (NYSE:QGEN) have earned a consensus recommendation of “Hold” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $49.6111.

A number of research analysts have recently commented on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 22nd. Wall Street Zen upgraded Qiagen from a “hold” rating to a “buy” rating in a research report on Sunday, December 21st. Citigroup lowered Qiagen from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $55.00 to $50.00 in a research note on Thursday, December 11th. Finally, Barclays reiterated an “overweight” rating and set a $55.00 price target (up previously from $53.00) on shares of Qiagen in a research report on Monday, December 15th.

Qiagen Stock Up 0.6%

Shares of NYSE QGEN opened at $45.64 on Thursday. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45. The company has a market cap of $10.14 billion, a P/E ratio of 24.80, a P/E/G ratio of 2.32 and a beta of 0.67. Qiagen has a 52 week low of $37.63 and a 52 week high of $51.88. The business has a 50-day simple moving average of $46.04 and a two-hundred day simple moving average of $47.10.

Qiagen’s stock is set to reverse split before the market opens on Thursday, January 8th. The 19-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, January 7th.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.58 by $0.03. The company had revenue of $532.58 million during the quarter, compared to analysts’ expectations of $525.68 million. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. Qiagen’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.57 earnings per share. Research analysts anticipate that Qiagen will post 2.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Qiagen

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in shares of Qiagen by 1.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,424,809 shares of the company’s stock worth $420,401,000 after acquiring an additional 172,062 shares during the last quarter. Amundi lifted its stake in Qiagen by 4.4% during the third quarter. Amundi now owns 4,290,273 shares of the company’s stock worth $201,471,000 after purchasing an additional 181,509 shares during the last quarter. Boston Partners purchased a new position in shares of Qiagen in the 3rd quarter worth about $179,450,000. Norges Bank purchased a new position in shares of Qiagen in the 2nd quarter worth about $158,728,000. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Qiagen by 5.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,874,356 shares of the company’s stock valued at $133,140,000 after purchasing an additional 141,393 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.